Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Sanofi to develop a mobile app for insulin patients

Will work with therapeutic companion software company Voluntis

Sanofi

Sanofi has expanded it alliance with a French therapeutic companion software company to develop a new mobile app for insulin patients.

The tool, which Sanofi characterises as a ‘digital insulin titration solution’, will be a mobile app that assists type 2 diabetes patients on basal insulin with decision-making and self-management.

The app will allow remote monitoring by a patient’s health care team and is set to be piloted in North America and several European countries.

Voluntis focuses on ‘embedding connectivity in therapeutics and medical intelligence in software’ and last year gained FDA clearance and the European CE mark for the new mobile app.

"Despite the availability of new medicines for the treatment of diabetes, we see thatoutcomes are not sufficiently improving and that more than half of patients are not well controlled,"

Peter Guenter, executive vice-president, diabetes and cardiovascular at Sanofi, said: "Sanofi is focusing on a beyond-the-pill approach. We know that diabetes management is a 24/7 job, and we recognise that the right tools need to be developed to realise better outcomes. The long-term alliance we have with Voluntis will help us to reach that goal."

The new agreement expands Sanofi’s existing alliance with Voluntis, which was established in 2011 and has seen the partners develop the Diabeo digital device to help patients manage their basal-bolus treatment.

Eric Elliott, chairman of Voluntis, said: "This new phase of our partnership with a world leader in diabetes will help us deliver digital titration tools into the hands of providers and their patients. F

“Furthermore, digital therapeutics allow manufacturers and payers to check whether agreed value metrics have been achieved and help to lower costs without compromising on patient outcomes and access. They ensure that prescription medications deliver the effects for which they were brought to market."

16th March 2017

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics